Carellizumab

2022 CSCO Guidelines Update Highlights: Immunotherapy Multi-line Options Are Abundant and Application Forward
immunity Chinese Society of Clinical Oncology csco Navuliyuzumab Carellizumab tumor
05-05
Lung cancer "no chemotherapy era" or will come to the lung cancer advanced survival or is expected to exceed 5 years?
lung cancer Advanced lung cancer chemotherapy Non-small cell lung cancer Terelizumab Carellizumab
04-29
Dialogue with Zhang Lianshan: Hengrui Pharmaceutical's long-term doctrine - R & D and innovation
Hengrui Pharmaceutical Zhang Lianshan Carellizumab Hengrui
04-20
When health science popularization is carried out 丨 vigilance against gluttony "disease from the mouth" expert Xu Jianping analyzed the key points of esophageal cancer prevention and treatment
Esophageal carcinoma Xu Jianping Carellizumab tumor
02-25
Which Chinese innovative drugs are expected to successfully enter the US market in 2022?
Innovative medicine United States pd-1 Pharmaceutical companies Carellizumab fda Chinese Medicine Clinical practice Henry
02-19
Authoritative release! The 2022 edition of the Primary Liver Cancer Diagnosis and Treatment Guidelines is here
Guidelines for the diagnosis and treatment of primary liver cancer hepatocarcinoma clinic Carellizumab Donafenib Sorafenib
01-24
Domestic immunotherapy drug carellizumab indications for a large inventory, covering 5 major cancer species
Carellizumab immunity Indications lymphoma hepatocarcinoma Esophageal carcinoma Nasopharyngeal carcinoma pd-1 Non-small cell lung cancer chemotherapy
12-21
Hengrui Pharmaceutical Carellizumab has added two new indications, and the total number of approved indications has reached 8
Hengrui Pharmaceutical Carelli Beads Carellizumab Indications Esophageal squamous cell carcinoma Esophageal carcinoma nsclc
12-16